Comparison of an Initial Risk-Based Testing Strategy vs Usual Testing in Stable Symptomatic Patients With Suspected Coronary Artery Disease
Pamela S. Douglas(Duke University), Jane Cao, W. Schuyler Jones(Duke University), Stephen R. Bloom(Imperial College London), Manesh R. Patel(Duke University), Eric Yow(Duke University), Sarah Mullen(HeartFlow (United States)), Stuart Pocock(London School of Hygiene & Tropical Medicine), Daniel B. Mark(Duke University), Beth Martinez(Duke University), Björn Redfors(Cornell University), Nick Curzen(University Hospital Southampton NHS Foundation Trust), Michael Barry(University Hospital Galway), Robert Pelberg, Christopher M. Kramer(American College of Cardiology), Campbell Rogers(HeartFlow (United States)), Ziad A. Ali(St. Francis Hospital), Anthony N. DeMaria(University of California System), Ori Ben‐Yehuda(University of San Diego), Michael G. Nanna(Yale University), Gregg W. Stone(Cardiovascular Institute of the South), Binita Shah(New York University), David Engel(Columbia University Irving Medical Center), Ozgu M. Issever, Bernard De Bruyne(Al-Azhar University), Yanhong Li, Michelle D. Kelsey(Duke University), Colin Berry(University of Glasgow), Melanie R. Daniels, Whitney Huey(HeartFlow (United States)), Christopher B. Fordyce(Vancouver General Hospital), Hussein R. Al‐Khalidi(Clinical Research Institute), Gianluca Pontone(University of Milan), Kevin J. Anstrom(University of North Carolina at Chapel Hill), Sreekanth Vemulapalli(Duke University), James E. Udelson(Tufts Medical Center), Shea E. Hogan(University of Colorado Denver), Robert A. Byrne(Mater Private Hospital), Robert W. Yeh(Beth Israel Deaconess Medical Center), Andrew M. Kahn(University of California San Diego), Marc P. Bonaca(The Medical Center of Aurora), Pál Maurovich‐Horvat(Semmelweis University), Jonathon Leipsic(University of British Columbia), Patricia A. Cowper(Duke University), V. Marinescu(Edward Hospital), Derek Chow, David Buck, Weibing Xing, John P. Greenwood(University of Leeds)
Cited by 97
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Abdominal Visceral and Subcutaneous Adipose Tissue Compartments
|Circulation|2007|2.9k